Hepatocyte nuclear factor-3 alpha (HNF-3α) negatively regulates androgen receptor transactivation in prostate cancer cells

Biochemical and Biophysical Research Communications

Volumn 367, Issue 2, 2008, Pages 481-486

  Lee, Hyun Joo ^a   Hwang, Miok ^a   Chattopadhyay, Soma ^a   Choi, Hueng Sik ^a   Lee, Keesook ^a  

^a Chonnam National University   (South Korea)

Author keywords

Androgen receptor; Cofactor; HNF 3 ; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; NUCLEAR RECEPTOR COACTIVATOR 2; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CONTROLLED STUDY; DOWN REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN INTERACTION; TRANSACTIVATION;

CELL LINE, TUMOR; DOWN-REGULATION; HEPATOCYTE NUCLEAR FACTOR 3-ALPHA; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TRANS-ACTIVATION (GENETICS);

EID: 38349062191     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.12.162     Document Type: Article

References (42)

1. Imhof A., Yang X.J., Ogryzko V.V., Nakatani Y., Wolffe A.P., and Ge H. Acetylation of general transcription factors by histone acetyltransferases. Curr. Biol. 7 (1997) 689-692
2. Sciarr A., Mariotti G., Gentile V., Voria G., Pastore A., Monti S., and Di Silverio F. Neuroendocrine differentiation in human prostate tissue: is it detectable and treatable?. Brit. J. Urol. Int. 91 (2004) 438-445
3. Bannister A.J., and Kouzarides T. The CBP co-activator is a histone acetyltransferase. Nature 384 (1996) 641-643
4. Brothman A.R., Lesho L.J., Somers K.D., Schellhammer P.F., Ladaga L.E., and Merchant D.J. Cytogenetic analysis of four primary prostatic cultures. Cancer Genet. Cytogenet. 37 (1989) 241-248
5. Jin B., Turner L., Walters W.A., and Handelsman D.J. The effects of chronic high dose androgen or estrogen treatment on the human prostate [corrected]. J. Clin. Endocrinol. Metab. 81 (1996) 4290-4295
6. Jeong B.C., Hong C.Y., Chattopadhyay S., Park J.H., Gong E.Y., Kim H.J., Chun S.Y., and Lee K. Androgen receptor corepressor-19 kDa (ARR19), a leucine-rich protein that represses the transcriptional activity of androgen receptor through recruitment of histone deacetylase. Mol. Endocrinol. 18 (2004) 13-25
7. Heinlein C.A., and Chang C. Androgen receptor (AR) coregulators: an overview. Endocr. Rev. 23 (2002) 175-200
8. Heinlein C.A., and Chang C. Androgen receptor in prostate cancer. Endocr. Rev. 25 (2004) 276-308
9. Wong C.L., Zhou Z.X., Sar M., and Wilson E.M. Steroid requirement for androgen receptor dimerization and DNA binding. Modulation by intramolecular interactions between the NH2-terminal and steroid-binding domains. J. Biol. Chem. 268 (1993) 19004-19012
10. Hong C.Y., Gong E.Y., Kim K., Suh J.H., Ko H.M., Lee H.J., Choi H.S., and Lee K. Modulation of the expression and transactivation of androgen receptor by the basic helix-loop-helix transcription factor Pod-1 through recruitment of histon deacetylase 1. Mol. Endocrinol. 19 (2005) 2245-2257
11. Hong C.Y., Park J.H., Ahn R.S., Im S.Y., Choi H.S., Soh J., Mellon S.H., and Lee K. Molecular mechanism of suppression of testicular steroidogenesis by proinflammatory cytokine tumor necrosis factor alpha. Mol. Cell Biol. 24 (2004) 2593-2604
12. Langley E., Zhou Z.X., and Wilson E.M. Evidence for an anti-parallel orientation of the ligand-activated human androgen receptor dimer. J. Biol. Chem. 270 (1995) 29983-29990
13. Miyamoto H., Messing E.M., and Chang C. Androgen deprivation therapy for prostate cancer: current status and future prospects. Prostate 61 (2004) 332-353
14. Agoulnik I.U., Vaid A., Nakka M., Alvarado M., Bingman W.E., Erdem H., Frolov A., Smith C.L., Ayala G.E., Ittmann M.M., and Weigel N.L. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Res. 66 (2006) 10594-10602
15. Kim J., and Coetzee G.A. Prostate specific antigen gene regulation by androgen receptor. J. Cell. Biochem. 93 (2004) 233-241
16. Lim J., Ghadessy F.J., Abdullah A.A., Pinsky L., Trifiro M., and Yong E.L. Human androgen receptor mutation disrupts ternary interactions between ligand, receptor domains, and the coactivator TIF2 (transcription intermediary factor2). Mol. Endocrinol. 14 (2000) 1187-1197
17. Mirosevich J., Gao N., Gupta A., Shappell S.B., Jove R., and Matusik R.J. Expression and role of Foxa proteins in prostate cancer. The Prostate 9999 (2005) 1-16
18. Mirosevich J., Gao N., and Matusik R.J. Expression of Foxa Transcription factors in the developing and adult murine prostate. The Prostate 62 (2005) 339-352
19. Carroll J.S., Liu X.S., Brodsky A.S., Li W., Meyer C.A., Szary A.J., Eeckhoute J., Shao W., Hestermann E.V., Geistlinger T.R., Fox E.A., Silver P.A., and Brown M. Some-Wide Mapping of Estrogen Receptor Binding Reveals Long-Range Regulation Requiring the Forkhead Protein FoxA1. Cell 122 (2005) 33-43
20. Kim J.Y., Kim H.J., Kim K.T., Park Y.Y., Seong H.A., Park K.C., Lee I.K., Ha H.J., Song M., Park S.C., and Choi H.S. Orphan nuclear receptor SHP represses hepatocyte nuclear factor 3 (HNF3)/Foxa transcription via inhibition of its DNA binding. Mol. Endocrinol. 18 (2004) 2880-2894
21. Ellwood-Yen K., Graeber T.G., Wongvipat J., Iruela-Arispe M.L., Zhang J., Matusik R., Thomas G.V., and Sawyers C.L. Myc-driven murin prostate cancer shares molecular features with human prostate tumors. Cancer Cell 4 (2003) 223-238
22. Kaestner K.H., Knochel W., and Martinez D.E. United nomenclature for the winged helix/forkhead transcription factors. Genes Dev. 14 (2000) 142-146
23. Nagy L., Kao H.Y., Chakravarti D., Lin R.J., Hassig C.A., Ayer D.E., Schreiber S.L., and Evans R.M. Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell 89 (1997) 373-380
24. Denis L.J., and Griffiths K. Endocrine treatment in prostate cancer. Semin. Surg. Oncol. 18 (2000) 52-74
25. Fu M., Wang C., Reutens A.T., Wang J., Angeletti R.H., Siconolfi-Baez L., Ogryzko V., Avantaggiati M.L., and Postell R.G. p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. J. Bio. Chem. 275 (2000) 20853-20860
26. Fu M., Rao M., Wang C., Sakamaki T., Wang J., Vizio D.D., Zhang X., Albanese C., Balk S., Chang C., Fan S., Rosen E., Palvimo J.J., Janne O.A., Muratoglu S., Avantaggiati M.L., and Pestell R.G. Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth. Mol. Cell Biol. 23 (2003) 8563-8575
27. Truss M., Bartsch J., Schelbert A., Hache R.J., and Beato M. Hormone induces binding of receptors and transcription factors to a rearranged nucleosome on the MMTV promoter in vivo. EMBO J. 14 (1995) 1737-1751
28. Gao N., Zhang J., Rao M.A., Case T.C., Mirosevich J., Wang Y., Jin R., Gupta A., Kinnie P.S., and Matusik R.J. The role of hepatocyte nuclear factor-3 alpha (Forkhead Box A1) and androgen receptor in transcriptional regulation of prostatic genes. Mol. Endocrinol. 17 (2003) 1484-1507
29. Gao N., Ishii K., Mirosevich J., Kuwajima S., Oppenheimer S.R., Roberts R.L., Jiang M., Yu X., Shappell S.B., Caprioli R.M., Stoffel M., Hayward S.W., and Matusik R.J. Forkhead box A1 regulates prostate ductal morphogenesis and promotes epithelial cell maturation. Development 132 (2005) 3431-3443
30. McKenna N.J., Lanz R.B., and O'Malley B.W. Nuclear receptor coregulators: cellular and molecular biology. Endocr. Rev. 20 (1999) 321-344
31. Carlsson P., and Mahlapuu M. Forkhead transcription factors: Key players in development and metabolism. Dev. Biol. 250 (2002) 1-23
32. Holmqvist P.H., Belikov S., Zaret K.S., and Wrange O. FoxA1 binding to the MMTV LTR modulates chromatin structure and transcription. Exp. Cell Res. 304 (2005) 593-603
33. Peterson R.S., Clevidence D.E., Ye H., and Costa R.H. Hepatocyte nuclear factor-3 alpha promoter regulation involves recognition by cell specific factors, thyroid transcription factor-1, and autoactivation. Cell Growth Differ. 8 (1997) 69-82
34. Chattopadhyay S., Gong E.Y., Hwang M., Park E., Lee H.J., Hong C.Y., Choi H.S., Cheong J.H., Kwon H.B., and Lee K. The CCAAT enhancer-binding protein-alpha negatively regulates the transactivation of androgen receptor in prostate cancer cells. Mol. Endocrinol. 20 (2006) 984-995
35. Dedhar S., Rennie P.S., Shago M., Haqesteijn C.Y., Yang H., Filmus J., Hawley R.G., Bruchovsky N., Cheng H., and Matusik R.J. Inhibition of nuclear hormone receptor activity by calreticulin. Nature 367 (1994) 480-483
36. Powell S.M., Christiaens V., Voulqaraki D., Waxman J., Claessens F., and Bevan C.L. Mechanisms of androgen receptor signaling via steroid receptor coactivator-1 in prostate. Endocr. Relat. Cancer 11 (2004) 117-130
37. Denmeade S.R., and Isaacs J.T. A history of prostate cancer treatment. Nat. Rev. Cancer 2 (2002) 389-396
38. Heinzel T., Lavinsky R.M., Mullen T.M., Soderstrom M., Laherty C.D., Torchia J., Yang W.M., Brard G., Ngo S.D., Davie J.R., Seto E., Eisenman R.N., Rose S.W., Glass C.K., and Rosenfeld M.G. A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature 387 (1997) 43-48
39. Ogryzko V.V., Schiltz R.L., Russanova V., Howard B.H., and Nakatani Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 87 (1996) 953-959
40. Tan Y., Hughes D., Wang X., and Costa R.H. Adenovirus-mediated increase in HNF-3α or HNF-3β shows differences in levels of liver glycogen and gene expression. Hepatology 35 (2002) 30-39
41. Hu Y.C., Yeh S., Yeh S.D., Sampson E.R., Huang J., Li P., Hsu C.L., Ting H.J., Lin H.K., Wang L., Kim E., Ni J., and Chang C. Functional domain and motif analyses of androgen receptor coregulator ARA70 and its differential expression in prostate cancer. J. Biol. Chem. 279 (2004) 33438-33446
42. Zhou Z.X., He B., Hall S.H., Wilson E.M., and French F.S. Domain interactions between coregulator ARA70 and the androgen receptor (AR). Mol. Endocrinol. 16 (2002) 287-300